Alternate-day fasting exacerbates doxorubicin cardiotoxicity in cancer chemotherapy.

Authors :: Pan H
Yang S
Cheng W
Cai Q
Shubhra QTH
Source :: Trends in endocrinology and metabolism: TEM [Trends Endocrinol Metab] 2023 Jul; Vol. 34 (7), pp. 392-394. Date of Electronic Publication: 2023 May 26.
Publication Year :: 2023
Abstract: Doxorubicin (Dox) is a highly potent chemotherapy drug. Despite its efficacy, Dox's clinical application is limited due to its association with significant complications, namely cardiotoxicity and the risk of heart failure. Recent intriguing findings by Ozcan et al. indicate that alternate-day fasting (ADF) significantly exacerbates the cardiotoxicity of Dox.<br />Competing Interests: Declaration of interests No interests are declared.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Subjects :: Humans
Antibiotics, Antineoplastic adverse effects
Doxorubicin adverse effects
Fasting
Myocytes, Cardiac
Apoptosis
Cardiotoxicity etiology
Cardiotoxicity drug therapy
Neoplasms drug therapy
Neoplasms complications

Full Text Access

Tools